Results 1 to 10 of about 59,585 (140)

Research Progress Towards Poliovirus Virus-like Particle Vaccines: A Review [PDF]

Vaccines
Poliovirus (PV), a historically significant enterovirus responsible for severe paralytic diseases, has seen its incidence dramatically reduced through widespread vaccination efforts, propelling global eradication initiatives.
Taoli Han, Jinbo Xiao, Shiyao Zhang, Tongyue Su, Yinuo Liu, Yong Zhang   +5 more
doaj   +2 more sources

Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2 [PDF]

npj Vaccines
The COVID-19 pandemic spurred mRNA vaccine innovation, but new SARS-CoV-2 variants highlight the need for vaccines with improved potency and durability.
Jason P. Laliberte, Yingyun Cai, Tara Kenny, Yi Zhang, Kuishu Ren, Kim Rosenthal, Daniel Flores, Richard Roque, Oliver Acton, Vanessa Cadevilla Peano, Noel Janney, Vinita Puri, Sarah Siddiqui, Angela Pack, Giune Padilla, Seme Diallo, Hibret Adissu, Rakesh Choudhary, Hawley Pruitt, Yi-Han Cheng, George Thom, Michael Newton, Cheyne Kurokawa, Johnathan Guest, Phillip Swanson, Yueh-Ming Loo, Joseph R. Francica, Wade Blair, Mark Esser   +28 more
doaj   +2 more sources

Virus-like Particle Vaccines and Platforms for Vaccine Development

Viruses, 2023
Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are ...
Milad Kheirvari, Hong Liu, Ebenezer Tumban   +2 more
doaj   +1 more source

Special Issue “Virus-Like Particle Vaccines”

Viruses, 2020
Virus-like particles (VLPs) have become a key tool for vaccine developers and manufacturers [...]
Monique Vogel, Martin F. Bachmann
doaj   +1 more source

Versatile virus-like particle carrier for epitope based vaccines. [PDF]

PLoS ONE, 2010
BACKGROUND: Recombinant proteins and in particular single domains or peptides are often poorly immunogenic unless conjugated to a carrier protein. Virus-like-particles are a very efficient means to confer high immunogenicity to antigens.
Alain C Tissot, Regina Renhofa, Nicole Schmitz, Indulis Cielens, Edwin Meijerink, Velta Ose, Gary T Jennings, Philippe Saudan, Paul Pumpens, Martin F Bachmann   +9 more
doaj   +1 more source

Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype [PDF]

, 2015
Seasonal epidemics caused by influenza A (H1 and H3 subtypes) and B viruses are a major global health threat. The traditional, trivalent influenza vaccines have limited efficacy because of rapid antigenic evolution of the circulating viruses.
Citron, Michael, Ferrara, Francesca, Flynn, Jessica A, Liang, Xiaoping, Mallajosyula, Vamsee V A, Temperton, Nigel J., Varadarajan, Raghavan   +6 more
core   +11 more sources

RNA Phage VLP-Based Vaccine Platforms

Pharmaceuticals, 2021
Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format.
David S. Peabody, Julianne Peabody, Steven B. Bradfute, Bryce Chackerian   +3 more
doaj   +1 more source

Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines

Vaccines, 2021
SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat ...
Acharya Balkrishna, Vedpriya Arya, Akansha Rohela, Ashwani Kumar, Rachna Verma, Dinesh Kumar, Eugenie Nepovimova, Kamil Kuca, Naveen Thakur, Nikesh Thakur, Pankaj Kumar   +10 more
doaj   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: Restoration of previously unpublished methodology [PDF]

, 2020
Purpose: Trustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine's risks and benefits.
Bourgeois, Florence, Doshi, Peter, Hong, Kyungwan, Jefferson, Tom, Jones, Mark, Lee, Haeyoung, Shamseer, Larissa, Spence, O'Mareen   +7 more
core   +1 more source